Traders should monitor the AACR presentations for data depth, especially durability of immune response and biomarker correlation, which could influence sentiment. Participation in partnering events may lead to future collaboration announcements, potentially serving as a catalyst.
Price Chart
Executive Summary
Evaxion announced two abstracts accepted for presentation at the AACR Annual Meeting, featuring new biomarker and immunogenicity data for its personalized cancer vaccine EVX-01 in melanoma, and preclinical data on using its AI-Immunology™ platform to target glioblastoma. The company will also participate in an industry partnering event, signaling efforts to advance collaborations.
Key Facts
- Two abstracts accepted for AACR 2026 presentation: one on EVX-01 clinical data in advanced melanoma, another on AI-identified neoantigens for glioblastoma.
- EVX-01 data includes durable de novo T-cell responses from a Phase 2 trial combining the vaccine with KEYTRUDA® (pembrolizumab).
- Glioblastoma research is preclinical, focusing on endogenous retrovirus (ERV)-derived neoantigens identified via AI-Immunology™.
- Evaxion will attend the AACR Oncology Industry Partnering event, indicating business development activity.
Financial Impact
No financial impact disclosed; data is clinical and preclinical with no revenue or cost figures provided.
Risk Factors
- No efficacy or survival data (e.g., overall survival, progression-free survival) disclosed in the release.
- Glioblastoma program is preclinical; clinical applicability remains uncertain.
- EVX-01 remains in Phase 2; no guarantee of regulatory or commercial success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257673 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access